Ross Muken

Evercore ISI maintained its Buy rating on Walgreens Boots Alliance Inc (NASDAQ: WBA) saying there is still chance of a reasonable outcome for both parties, despite the amendment to the merger, due to a material drop in the EBITDA/financial conditions of Rite Aid Corporation (NYSE: RAD). The...

Shares of Walgreen Company (NYSE: WAG) surged over 3 percent Tuesday to $77.13 after beating Q1 earnings expectations. ISI Group’s Ross Muken noted that Walgreen’s management “expressed commitment to specialty infusion business” on the earnings conference call. The...

In a report published Thursday, ISI Group analyst Ross Muken upgraded the rating on ICON plc (NASDAQ: ICLR) from Buy to Strong Buy, and reiterated the $49.00 price target. In the report, ISI Group noted, “Tuesday evening one of ICLR's close CRO competitors, PRXL, released weaker than anticipated...

In a report published Friday, ISI Group analyst Ross Muken upgraded the rating on PAREXEL International Corporation (NASDAQ: PRXL) from Neutral to Buy, and raised the price target from $52.50 to $57.00. In the report, ISI Group noted, “As we approach 3Q earnings, dynamics in the CRO and biopharma...

In a report published on Tuesday, International Strategy & Investment Group analyst Ross Muken initiated coverage on PAREXEL (NASDAQ: PRXL) with a Neutral rating and a $50 PT. In the report, ISI noted that, "Impressive top-line growth at PRXL (>20% in FY13E) has been driven by a robust...

Deutsche Bank analysts Ross Muken, Michael Cherny, and Vijay Kumar reiterated a Buy rating and %78 price target for Medco (NYSE: MHS). The analysts see sustained growth at Medco, driven by several drivers, including growth in generics, mail, and PGx. They said, "While there is some debate on the...

Deutsche Bank Securities analysts Ross Muken, Michael Cherny and Vijay Kumar reiterated their Buy rating for shares of MedcoHealth Solutions Inc (NYSE: MHS), with a price target of $78 per share. The analysts reiterated their Buy rating for MedcoHealth Solutions Inc after the company's board of...

Merck KGaA (ADR) (OTC: MKGAY), the Germany based drug company, agreed to buy Millipore Corp. (NYSE: MIL), a life science company, for about $6 billion. Millipore is valued at $107 per share, which is 13 percent higher than the company’s closing price on Feb 26. According to Merck spokeswoman...